Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
Dryocrassin ABBA We acknowledge some important limitations t
2022-01-13

We acknowledge some important limitations to the study. Given that SEER is a national database of abstracted clinical information, there is selection bias as to which patients underwent RS testing. As clinicians are selecting which patients to test, the RS distributions may not reflect the true dist
-
reference 2 br Discussion br Conflict of
2022-01-13

Discussion Conflict of interest Acknowledgements We thank Rosetta Barkley for expert technical assistance. We thank Robin Maser, James Calvet, Darren Wallace, and Jovanka Koo for many helpful discussions and expert technical advice. This work was supported by National Institutes of Health,
-
Assays can perform differently by genotype and under
2022-01-13

Assays can perform differently by Methicillin sodium salt and under-quantification of HCV GTs has been seen with HCV assays [8], [9], [10], [11]. Under-quantification of GT4 has been reported in some early studies of the VERIS Assay [7], [12] where a bias greater than −0.5 log10IU/mL was seen. In tw
-
br Discussion As expected RAS prevalence for treatment
2022-01-13

Discussion As expected, RAS prevalence for treatment-experienced patients who failed therapy with first-wave, first-generation drugs telaprevir/boceprevir was higher compared to non-experienced patients likely due to drug-selective pressure. For non-responders to previous therapy, resistance subs
-
In first wave first generation drugs telaprevir and boceprev
2022-01-13

In 2013, first-wave, first-generation drugs telaprevir and boceprevir was the first protease inhibitors (PIs) incorporated in Brazilian Clinical Guidelines for the treatment of patients infected with HCV rxr receptor 1. Based on this 2013 Clinical Guideline, telaprevir could be used for both naïve a
-
To test this concept we took advantage of
2022-01-13

To test this concept, we took advantage of our large supply of various 2-pyridyl containing [3.1.0] cores (inactive with alkyl or aryl sulfonamides) and prepared the -methylimidazole sulfonamide analogs and (), as work form Merck demonstrated that the 2-pyridyl moiety was superior to the original
-
For molecules with potential for
2022-01-13

For molecules with potential for therapeutic use, high potency is desired, preferably in the nM or lower concentration range. However, the glycine receptor specific peptides identified with the New England Biolabs Ph.D. libraries, both in this study (Fig. 3) and by Tipps et al. (2010), acted at low
-
In order to discover novel
2022-01-12

In order to discover novel small-molecule compounds with the activity of GLUT4 translocation, we conducted a cell-based phenotype screening in L6-GLUT4-myc myoblasts by measuring appearance of GLUT4 on the plasma membrane (GLUT4 translocation activity). Evaluation of total 183,400 compounds gave sev
-
This hypothesis is in line with our phylogenetic
2022-01-12

This hypothesis is in line with our phylogenetic analysis of FBPase sequences which revealed that vertebrate FBP2 evolved significantly faster than FBP1 (Fig. 2). An average distance between FBP2 and ancestral vertebrate FBPase was higher than that for FBP1. Moreover, preliminary study on amphibia
-
Recently results obtained by our group have demonstrated
2022-01-12

Recently, results obtained by our group have demonstrated that hEECs are able to secrete NPY into the extracellular medium and that this peptide can induce an increase in the [Ca]i of these cells (Jacques et al., 2003b). In light of these results and those obtained in this study, we can speculate th
-
Two typical properties of Gi
2022-01-12

Two typical properties of Gi/o protein-coupled receptors, namely an increase in 35S-GTPγS binding (Strange, 2010) and an inhibition of exocytotic noradrenaline release (Schlicker and Göthert, 1998), were not shared by H4 receptor activation on cortical membranes (guinea-pig and mouse) and cortical s
-
br Experimental br Results br
2022-01-12

Experimental Results Discussion In this study, we performed molecular docking analysis and in vitro studies to determine whether genistein binds to HIF-1α in BC Ki16425 and identify the residues involved in this interaction. We found that some functional groups (residues) mimic the binding
-
HER genotype was determined in breast cancer tissue of breas
2022-01-12

HER2 genotype was determined in breast cancer tissue of 73 breast cancer patients. As previously reported, Ile655Val and Ala1170Pro genotypes measured in breast cancer tissues were available for 71 and 69 breast cancer patients, respectively. Briefly, 77.5% (55/71) of patients were homozygous for t
-
CD CD belong to the costimulatory adhesion molecule family
2022-01-12

CD80/CD86 belong to the costimulatory adhesion molecule family, which can activate T SB 290157 trifluoroacetate salt australia by the costimulatory pathway and have been used as indicators of DC maturation in numerous studies. In addition, MHC-II, as the principal component of antigen presentation,
-
Given the overexpression of HO in some tumors
2022-01-12

Given the overexpression of HO-1 in some tumors, such as CML, and its potential involvement in chemoresistance to classical chemotherapeutic agents, compounds 4 and 8f were tested in CML cell lines resistant to IM, a classical TK inhibitor used in CML. Compounds 4 and 8f, in combination with IM, sho
14379 records 500/959 page Previous Next First page 上5页 496497498499500 下5页 Last page